Search

Author/Creator Smith, Sean

4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors. (9th November 2020)

Authors:
Metz, Heather; Brender, Ty; Stevens, Brenda; Winship, Damion; Brevik, Jamie; Comeau, Michael; Childs, Monica; Chang, Jenny; Fan, Li-Qun; Xu, Hengyu; Grey, Jonathan; Adamo, Jeffrey; Setter, Ben; Carrillo, Ray; Smith, Sean; Tan, Phil; DuBose, Robert; Latchman, Yvette; Baum, Peter; Odegard, Valerie
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A754
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors. (9th November 2020)

Authors:
Metz, Heather; Brender, Ty; Stevens, Brenda; Winship, Damion; Brevik, Jamie; Comeau, Michael; Childs, Monica; Chang, Jenny; Fan, Li-Qun; Xu, Hengyu; Grey, Jonathan; Adamo, Jeffrey; Setter, Ben; Carrillo, Ray; Smith, Sean; Tan, Phil; DuBose, Robert; Latchman, Yvette; Baum, Peter; Odegard, Valerie
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A427
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗